Association between disease-modifying antirheumatic drugs for rheumatoid arthritis and risk of incident dementia: a systematic review with meta-analysis.

42–44 In a randomised controlled trial of 41 patients with AD, subcutaneous etanercept 50 mg once weekly showed a trend toward improvements in the Mini-Mental State Exam score (p = 0.07) and neuropsychiatric inventory (p=0.02). 45 In another study, 15 patients with AD were randomised to receive etanercept 25 mg twice a week (n=8) or adalimumab twice a month (n=7) subcutaneously.

also in 53,322 other papers